摘要
目的分析妊娠期高血压患者采用硫酸镁联合拉贝洛尔的临床疗效及对妊娠结局的影响。方法选取2020年1月—2021年12月郑州市第一人民医院妇产科收治的妊娠期高血压150例患者,根据用药的不同,将单用硫酸镁治疗的50例作为对照1组,将单用拉贝洛尔治疗的50例作为对照2组,将联合使用硫酸镁与拉贝洛尔治疗的50例作为观察组。比较3组疗效、血液黏度、蛋白尿量、血清炎性因子水平、妊娠不良结局。结果观察组治疗总有效率96.00%,高于对照1组(76.00%)与对照2组(74.00%),差异有统计学意义(P<0.05);2组治疗前差异无统计学意义,P>0.05,治疗后观察组舒张压及收缩压分别为(78.15±6.04)mm Hg及(117.03±13.12)mm Hg,均低于对照1组[(87.15±6.14)mm Hg及(139.22±16.83)mm Hg]与对照2组[(88.05±6.43)mm Hg及(138.96±16.54)mm Hg],均P<0.05,对照1组与对照2组无差异,P>0.05;两组治疗前无差异,P>0.05,治疗后观察组患者血液黏度、蛋白尿量分别为(2.23±0.98)mPa·s及(1.01±0.19)g/24 h,均低于对照1组与对照2组,均P<0.05,对照1组与对照2无差异,P>0.05;观察组治疗后血清胱抑素、血清同型半胱氨酸及血清白细胞介素等炎性因子水平低于对照1组与对照2组,均P<0.05;观察组妊娠不良结局发生率(2%),显著低于对照1组(24%)与对照2组(18%),P<0.05。结论妊娠期高血压患者硫酸镁与拉贝洛尔联合治疗不仅能够控制血压、降低患者血液黏度、蛋白尿量与血清炎性因子水平,同时有利于改善妊娠结局。
Objective To analyze the effect of magnesium sulfate alone,labetalol alone and their combination on the effective rate in hypertensive patients during pregnancy.Methods A total of 150 patients with gestational hypertension who received treatment in our hospital from January 2020 to December 2021 were divided into control group 1,control group 2 and observation group.control group 1 was treated with magnesium sulfate alone,control group 2 was treated with labeolol alone,and observation group was treated with magnesium sulfate and labeolol combined.The effective rate,blood pressure,blood viscosity,albuminuria,serum inflammatory factors and adverse pregnancy outcome of three groups were compared.Results The total effective rate of observation group was 96.00%,higher than 76.00%of control group 1 and 74.00%of control group 2,P<0.05;There was no difference between the two groups before treatment,P>0.05.After treatment,the diastolic blood pressure and systolic blood pressure in the observation group were(78.15±6.04)mm Hg and(117.03±13.12)mm Hg,respectively.(87.15±6.14)mm Hg and(139.22±16.83)mm Hg in control group 1 and(88.05±6.43)mm Hg and(138.96±16.54)mm Hg in control group 2,all P<0.05.There was no difference between control group 1 and control group 2,P>0.05.After treatment,blood viscosity and proteinuria in observation group were(2.23±0.98)mPa·s and(1.01±0.19)g/24 h,respectively.They were lower than those in control group 1(4.05±1.14)mPa·s and(2.31±0.59)g/24 h and those in control group 2(3.98±1.06)mPa·s and(2.33±0.61)g/24 h,all P<0.05.There was no difference between control group 1 and control group 2(P>0.05).After treatment,the levels of serum cystatin,serum homocysteine and serum interleukin were(1.08±0.19)mg/L,(13.39±2.39)mmol/L and(24.26±2.35)pg/L,respectively.Compared with control group 1(1.63±0.30)mg/L,(18.58±2.74)mmol/L and(34.33±2.49)pg/L and control group 2(1.62±0.33)mg/L,(18.43±2.95)mmol/L and(35.02±2.01)pg/L,P<0.05;The incidence of adverse pregnancy outcomes in observation group was 2%,which was significantly lower than 24%in control group 1 and 18%in control group 2,P<0.05.Conclusion The combined treatment of magnesium sulfate and labetalol can not only reduce the blood viscosity,albuminuria volume and serum inflammatory factor level,but also effectively control the blood pressure level of patients with gestational hypertension,which has a positive effect on the improvement of pregnancy outcome.
作者
刘玉霞
LIU Yu-xia(Department of Obstetrics and Gynecology,Zhengzhou the First Peoples Hospital,Zhengzhou 450000,China)
出处
《医药论坛杂志》
2022年第9期38-41,共4页
Journal of Medical Forum
基金
河南省医学科技攻关计划普通项目(2020141128)。
关键词
硫酸镁单用
拉贝洛尔单用
联合用药
妊娠期高血压
治疗有效率
Magnesium sulfate alone
Labelolol alone
Drug combination
Hypertension during pregnancy
Therapeutic response rate
